Safranin O and toluidine blue histology. by Melissa A. MacIver (12850566)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Toluidine blue histology of cMSC constructs for initial chondrogenic screening. by Melissa A. MacIver (12850566)

Subjects:

Increase of the MDA content and expression regulation of <i>PgNAC</i> transcripts induced by cold treatment in ginseng hairy roots. by Qian Liu (135614)

Linear regressions of consumer stable carbon and nitrogen isotope values and collection date. by Nathan D. McTigue (10706460)

Subjects:

Symbiodiniaceae cell density of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i>, areal chlorophyll content of (C) <i>Acropora</i> sp. and (D) <i>P. verrucosa</i>, and chlorophy... by Malte Ostendarp (13217973)

The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. by Simon K. Schnyder (16632244)

MC depletion decreases aneurysmal growth after dissections in ApoE-RMB mice. by Alexia Loste (17592915)

Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments by Steven R. Shuken (14500192)

“…The tremendous false discovery rate (FDR) benefit of correction was confirmed in a range of different contexts. No correction method can guarantee a low FDP in a single experiment, but the probability of a high FDP is small when a high number and proportion of corrected <i>p</i>-values are significant. …”

Proportion of genotype calls with both alleles correct (2), one allele incorrect (1) and two alleles incorrect (0) at different sequencing coverages. by Harrison J. Lamb (11722247)

Virions with increased NA content elicit a more balanced NA and HA response. by Jin Gao (160559)

Increasing the Throughput of a High-Content Imaging-Based Developmental Neurotoxicity Proliferation Assay by Gabrielle Byrd (12462406)

Survival probability of cercariae in 0.38 ppt, 1.9 ppt, 3.8 ppt, and 5.7 ppt salinity treatments over a 24-hour period. by Ao Yu (1348512)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). by Willem Kaijser (12872371)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Sustainable Collagen Blends with Different Ionic Liquids for Resistive Touch Sensing Applications by Mireia Andonegi (14855252)

“…Collagen/[Ch][Seri] samples display the most pronounced decrease of the tensile strength (3.2 ± 0.4 MPa) and an increase of the elongation at break (50.6 ± 1.5%). …”

Variation of UCS with SHMP content. by Chenhao Li (822769)

“…Although increasing SHMP content improved the early strength, it led to a decrease in later strength, with the maximum late strength observed at 2% SHMP. …”